Disease-Modifying Therapies

Mechanism

Related News

Alnylam enters $1.23 billion discovery collaboration with Tenaya Therapeutics

May 14, 2026

Alnylam Pharmaceuticals entered a $1.23 billion discovery collaboration with Tenaya Therapeutics to identify up to 15 novel genetic targets for heart disease. The agreement includes $10 million upfront and up to $1.13 billion in milestone payments.

CAR T-cell therapy trial for progressive MS now recruiting; stem cell transplant trials advance

Mar 06, 2026

A Phase 1 trial of azer-cel, a CAR T-cell therapy using donor T-cells to target B-cells, is recruiting patients with progressive multiple sclerosis at eight U.S. sites. Separately, multiple randomized trials are comparing hematopoietic stem cell transplantation against high-efficacy disease-modifying therapies.